IRLAB Therapeutics AB held its Extraordinary General Meeting today, Friday, 5 June 2026.
The following main resolutions were made at the general meeting.
Approval of the Board of Directors' resolutions on issues of new shares of series A, with preferential rights for existing shareholders and with deviation from the shareholders' preferential rights, respectively, as well as amendment of the articles of association
The general meeting resolved to approve the Board of Directors' resolution from 5 May 2026 on an issue of new shares of series A with preferential rights for existing shareholders, and an issue of new shares of series A with deviation from the shareholders' preferential rights. The general meeting further resolved to adopt new articles of association, whereby the intervals for the share capital and the number of shares are amended to enable the issues of new shares.
Election of new Board members and board remuneration
The general meeting resolved, in accordance with the Nomination Committee's proposal, to elect Jan-Fredrik Backman and James Gamgort as new Board members. Following the general meeting, the Board of Directors consists of Carola Lemne, Christer Nordstedt, Gunnar Olsson, Rein Piir, Veronica Wallin, Jan-Fredrik Backman and James Gamgort. The Board of Directors thus consists of seven Board members for the period until the end of the next Annual General Meeting.
The general meeting further resolved, in accordance with the Nomination Committee's proposal, that Jan-Fredrik Backman and James Gamgort shall be remunerated at the same level as the current ordinary Board members in accordance with the resolution from the Annual General Meeting 2025, however, that the remuneration shall be reduced proportionally to only cover the remaining days from the election at the Extraordinary General Meeting until the next Annual General Meeting.
Minutes and complete resolutions
The minutes from the general meeting, including the complete resolutions, will be available on the company's website (www.irlab.se).